Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Azithramycine
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Farthing C et al. | Azithromycin for cerebral toxoplasmosis. | 1992 | Lancet | pmid:1346707 |
Chave JP et al. | Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. | 1992 | Antimicrob. Agents Chemother. | pmid:1324635 |
Derouin F et al. | Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis. | 1992 | Antimicrob. Agents Chemother. | pmid:1324642 |
Vallée E et al. | Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infection. | 1992 | Antimicrob. Agents Chemother. | pmid:1324644 |
Mertens JC et al. | Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. | 1992 | Antimicrob. Agents Chemother. | pmid:1324645 |
Hammerschlag MR et al. | In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. | 1992 | Antimicrob. Agents Chemother. | pmid:1324650 |
Paulsen P et al. | Influence of azithromycin and other macrolides on the intracellular killing of Staphylococcus aureus by human polymorphonuclear leucocytes of healthy donors and a patient with Chédiak-Higashi syndrome. | 1992 | Chemotherapy | pmid:1324831 |
Pajukanta R et al. | In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans. | 1992 | Antimicrob. Agents Chemother. | pmid:1329617 |
Bonnet M and Van der Auwera P | In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence. | 1992 | Antimicrob. Agents Chemother. | pmid:1329619 |
Neu HC | New macrolide antibiotics: azithromycin and clarithromycin. | 1992 | Ann. Intern. Med. | pmid:1310839 |
Massarotti EM et al. | Treatment of early Lyme disease. | 1992 | Am. J. Med. | pmid:1313637 |
Pruul H and McDonald PJ | Potentiation of antibacterial activity of azithromycin and other macrolides by normal human serum. | 1992 | Antimicrob. Agents Chemother. | pmid:1317141 |
Brown BA et al. | Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. | 1992 | Antimicrob. Agents Chemother. | pmid:1317144 |
Kobrehel G et al. | Synthesis and antibacterial activity of O-methylazithromycin derivatives. | 1992 | J. Antibiot. | pmid:1317368 |
Welsh LE et al. | In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae. | 1992 | Antimicrob. Agents Chemother. | pmid:1318677 |
Bahal N and Nahata MC | The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. | 1992 | Ann Pharmacother | pmid:1318761 |
Drew RH and Gallis HA | Azithromycin--spectrum of activity, pharmacokinetics, and clinical applications. | 1992 | Pharmacotherapy | pmid:1319048 |
Felstead SJ and Daniel R | Short-course treatment of sinusitis and other upper respiratory tract infections with azithromycin: a comparison with erythromycin and amoxycillin. European Azithromycin Study Group. | 1991 Sep-Oct | J. Int. Med. Res. | pmid:1660823 |
Daniel R | Simplified treatment of acute lower respiratory tract infection with azithromycin: a comparison with erythromycin and amoxycillin. European Azithromycin Study Group. | 1991 Sep-Oct | J. Int. Med. Res. | pmid:1660824 |
Kimata I et al. | Chemotherapeutic effect of azithromycin and lasalocid on Cryptosporidium infection in mice. | 1991 Nov-Dec | J. Protozool. | pmid:1667931 |